Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A
Paediatric and Autoimmune Endocrine Diseases Unit, Bambino Gesù Children's Hospital, Research Institute, Roma, Italy.
Horm Res. 2007;68(2):83-90. doi: 10.1159/000100371. Epub 2007 Feb 28.
In Prader-Willi syndrome (PWS) growth hormone therapy (GHT) improves height, body composition, agility and muscular strength. In such patients it is necessary to consider the potential diabetogenic effect of GHT, since they tend to develop type 2 diabetes, particularly after the pubertal age. The aim of our study was to investigate the effects of GHT on glucose and insulin homeostasis in PWS children. An oral glucose tolerance test (OGTT) was performed in 24 prepubertal PWS children (15 male, 9 female, age: 5.8 +/- 2.8 years), 16 were obese (group A) and 8 had normal weight (group B), before and after 2.7 +/- 1.3 years GHT (0.22 +/- 0.03 mg/kg/week) and, only at baseline, in 35 prepubertal children with simple obesity (19 male, 16 female) (group C). Fasting glucose and insulin, glucose tolerance, insulin sensitivity index (ISI), homeostasis model assessment of insulin resistance (HOMA-IR), quick insulin check index (QUICKI), area under the curves (AUC) of glucose and insulin were estimated. At the start of GHT, all PWS children were normoglycaemic and normotolerant but two developed impaired glucose tolerance after 2.2 and 1.9 years of therapy, respectively. At baseline, group A showed lower fasting insulin levels, HOMA-IR and AUC of insulin, higher ISI, QUICKI and AUC of glucose than group C. Comparing groups A and B, AUC of insulin was higher and ISI lower in group A. During GHT, a significant increase of fasting insulin and glucose, a worsening of insulin resistance (HOMA-IR) and insulin sensitivity (QUICKI) was found only in group A while ISI did not change. The AUC of glucose decreased in both groups instead AUC of insulin did not change. BMI-SDS decreased in group A and increased in group B. The increased insulin resistance and decreased insulin sensitivity in obese PWS patients, as well as the occurrence of impaired glucose tolerance during GHT, suggest that a close monitoring of glucose and insulin homeostasis is mandatory, especially in treated obese PWS children.
在普拉德-威利综合征(PWS)中,生长激素治疗(GHT)可改善身高、身体成分、敏捷性和肌肉力量。对于此类患者,有必要考虑GHT的潜在致糖尿病作用,因为他们容易患2型糖尿病,尤其是在青春期后。我们研究的目的是调查GHT对PWS儿童葡萄糖和胰岛素稳态的影响。对24名青春期前PWS儿童(15名男性,9名女性,年龄:5.8±2.8岁)进行了口服葡萄糖耐量试验(OGTT),其中16名肥胖(A组),8名体重正常(B组),在接受2.7±1.3年GHT(0.22±0.03mg/kg/周)之前和之后进行,并且仅在基线时,对35名青春期前单纯性肥胖儿童(19名男性,16名女性)(C组)进行了测试。估计了空腹血糖和胰岛素、葡萄糖耐量、胰岛素敏感性指数(ISI)、胰岛素抵抗稳态模型评估(HOMA-IR)、快速胰岛素检测指数(QUICKI)、葡萄糖和胰岛素曲线下面积(AUC)。在GHT开始时,所有PWS儿童血糖正常且糖耐量正常,但分别在治疗2.2年和1.9年后有两名儿童出现糖耐量受损。在基线时,A组的空腹胰岛素水平、HOMA-IR和胰岛素AUC较低,ISI、QUICKI和葡萄糖AUC高于C组。比较A组和B组,A组的胰岛素AUC较高,ISI较低。在GHT期间,仅在A组中发现空腹胰岛素和葡萄糖显著增加,胰岛素抵抗(HOMA-IR)和胰岛素敏感性(QUICKI)恶化,而ISI没有变化。两组的葡萄糖AUC均下降,而胰岛素AUC没有变化。A组的BMI-SDS下降,B组的BMI-SDS上升。肥胖PWS患者胰岛素抵抗增加和胰岛素敏感性降低,以及在GHT期间出现糖耐量受损,表明必须密切监测葡萄糖和胰岛素稳态,尤其是在接受治疗的肥胖PWS儿童中。